Oncobiologics (OTLK) Projected to Post Quarterly Earnings on Friday

Oncobiologics (NASDAQ:OTLK) is anticipated to announce its Q1 2026 results before the market opens on Friday, February 13th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $3.1380 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, February 19, 2026 at 4:00 PM ET.

Oncobiologics (NASDAQ:OTLK) last posted its quarterly earnings data on Friday, December 19th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. The business had revenue of $4.65 million during the quarter, compared to analysts’ expectations of $5.85 million. On average, analysts expect Oncobiologics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Oncobiologics Price Performance

Shares of Oncobiologics stock opened at $0.42 on Wednesday. The firm has a market cap of $30.94 million, a PE ratio of -0.28 and a beta of 0.10. Oncobiologics has a 1 year low of $0.38 and a 1 year high of $3.39. The stock has a fifty day moving average price of $1.15 and a 200-day moving average price of $1.38.

Institutional Trading of Oncobiologics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. lifted its holdings in shares of Oncobiologics by 865.2% in the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after buying an additional 21,941 shares in the last quarter. AQR Capital Management LLC increased its holdings in Oncobiologics by 42.7% during the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock worth $103,000 after acquiring an additional 25,351 shares during the period. Finally, Goldman Sachs Group Inc. lifted its stake in Oncobiologics by 74.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after purchasing an additional 44,063 shares in the last quarter. 11.20% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

OTLK has been the topic of a number of research analyst reports. Wall Street Zen cut shares of Oncobiologics from a “hold” rating to a “sell” rating in a research note on Saturday, January 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Oncobiologics in a research note on Monday, December 29th. Finally, Ascendiant Capital Markets increased their price objective on Oncobiologics from $8.00 to $10.00 and gave the company a “buy” rating in a report on Monday, December 22nd. One analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Oncobiologics presently has a consensus rating of “Hold” and a consensus target price of $5.33.

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.